Literature DB >> 30468097

Review of studies reporting actual prices for medicines.

Nika Mardetko1, Mitja Kos1, Sabine Vogler2.   

Abstract

BACKGROUND: Medicine purchasing and pricing decisions usually rely on officially published prices. Literature has reported evaluations of publicly stated prices. However, due to the frequent use of confidential price arrangements there are indications for paucity of data on actual medicine prices. Therefore, the study aimed to systematically review literature with regard to availability of information on actual medicine prices. AREAS COVERED: The Medline database was searched systematically to identify studies addressing actually paid prices of medicines used in-patient or out-patient care from the health care payer, health provider, or patient perspective, published during 2007-2017. A total of 33 observational studies were included in the analysis. EXPERT COMMENTARY: The review confirmed the paucity of studies on actual medicine prices, with only few studies evaluating differences between official and actually paid prices. The included studies are heterogeneous and differ in their design and focus. Non-availability of actual price data in several non-European countries results from lack of price regulation, which usually coincides with variation in actual prices for the same medicines between different dispensaries. In high-income, mostly European countries, transparency of actual prices is limited due to increased use of confidential medicine price arrangements.

Entities:  

Keywords:  Actual prices; confidentiality; discount; medicine price; price study; transparency

Mesh:

Substances:

Year:  2018        PMID: 30468097     DOI: 10.1080/14737167.2019.1552137

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  4 in total

1.  The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment.

Authors:  Dominik J Wettstein; Stefan Boes
Journal:  Health Econ Rev       Date:  2020-05-21

2.  Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.

Authors:  Dominik J Wettstein; Stefan Boes
Journal:  BMC Health Serv Res       Date:  2021-03-16       Impact factor: 2.655

3.  Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability.

Authors:  Suaad Almajed; Nora Alotaibi; Sana Zulfiqar; Zahraa Dhuhaibawi; Niall O'Rourke; Richard Gaule; Caoimhe Byrne; Aaron M Barry; Dylan Keeley; James F O'Mahony
Journal:  Eur J Health Econ       Date:  2021-08-30

4.  Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Authors:  Eirik Joakim Tranvåg; Øystein Ariansen Haaland; Bjarne Robberstad; Ole Frithjof Norheim
Journal:  JAMA Netw Open       Date:  2022-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.